Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene–related peptide inhibitors vs other preventive migraine treatments in the United States

In this study, patients taking calcitonin gene–related peptide monoclonal antibody (CGRP mAb) or galcanezumab (one of the CGRP mAbs) had higher costs than patients on standard of care (SOC). CGRP mAb and galcanezumab users had fewer outpatient acute and preventive migraine drug fills than SOC users....

Full description

Saved in:
Bibliographic Details
Published in:Journal of managed care & specialty pharmacy 2022-08, Vol.28 (8), p.818-829
Main Authors: Varnado, Oralee J, Manjelievskaia, Janna, Ye, Wenyu, Perry, Allison, Schuh, Kory, Wenzel, Richard
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, patients taking calcitonin gene–related peptide monoclonal antibody (CGRP mAb) or galcanezumab (one of the CGRP mAbs) had higher costs than patients on standard of care (SOC). CGRP mAb and galcanezumab users had fewer outpatient acute and preventive migraine drug fills than SOC users. Because of the reduced number of outpatient acute and preventive migraine drug fills, significant cost savings occurred among CGRP mAb and galcanezumab users in their respective cohorts compared with patients on SOC treatment.
ISSN:2376-0540
2376-1032
DOI:10.18553/jmcp.2022.28.8.818